Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 11/20 | 0.72 |
| ▸ | CTSK | P43235 | 9/20 | 0.72 |
| ▸ | CTSL | P07711 | 3/20 | 0.72 |
| ▸ | CTSB | P07858 | 2/20 | 0.72 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.60 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.51 |
| ▸ | REN | P00797 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | CA7 | P43166 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10944684 | 1.00 | CTSS (0.72) | CTSSCTSKCTSLCTSBCAPN1 | |
| SCHEMBL22193432 | 0.89 | CTSS (0.59) | CTSSCTSKCTSLCTSBCAPN1 | |
| SCHEMBL14918898 | 0.89 | CTSS (0.58) | CTSSCTSKCTSLCTSBCAPN1 | |
| SCHEMBL14932672 | 0.88 | CTSK (0.68) | CTSSCTSKCTSLCTSBCAPN1 | |
| SCHEMBL15522580 | 0.88 | CTSK (0.68) | CTSSCTSKCTSLCTSBCAPN1 | |
| SCHEMBL12452467 | 0.88 | CTSS (0.68) | CTSSCTSKCTSLCTSBCAPN1 | |
| SCHEMBL10904211 | 0.87 | CTSS (0.67) | CTSSCTSKCTSLCTSBCAPN1 | |
| SCHEMBL9037393 | 0.87 | CTSS (0.67) | CTSSCTSKCTSLCTSBCAPN1 | |
| SCHEMBL25869316 | 0.87 | CTSK (0.58) | CTSSCTSKCTSLCTSBCAPN1 | |
| SCHEMBL25869357 | 0.86 | CTSK (0.57) | CTSSCTSKCTSLCTSBCAPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 84 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116874803-A | Antibacterial dendritic polyester polymer and preparation method and application thereof | 清华大学深圳国际研究生院 | 2023-10-13 | — | — | CN | claimed |
| US-20260091024-A1 | PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE | BIOHAVEN THERAPEUTICS LTD (US) | 2026-04-02 | — | — | US | disclosed |
| US-20260041673-A1 | PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE | BIOHAVEN THERAPEUTICS LTD (US) | 2026-02-12 | — | — | US | disclosed |
| US-12492422-B2 | Ex vivo protease activity detection for disease detection/diagnostic, staging, monitoring and treatment | Sunbird Bio, Inc. (US) | 2025-12-09 | — | — | US | disclosed |
| US-12472165-B2 | Riluzole prodrugs and their use | BIOHAVEN THERAPEUTICS LTD. (VG) | 2025-11-18 | — | — | US | disclosed |
| US-20250332148-A1 | RILUZOLE PRODRUGS AND THEIR USE | BIOHAVEN THERAPEUTICS LTD (US) | 2025-10-30 | — | — | US | disclosed |
| US-12295942-B2 | Riluzole prodrugs and their use | BIOHAVEN THERAPEUTICS LTD. (VG) | 2025-05-13 | — | — | US | disclosed |
| US-12213965-B2 | Riluzole prodrugs and their use | BIOHAVEN THERAPEUTICS LTD. (VG) | 2025-02-04 | — | — | US | disclosed |
| EP-4425181-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTE | Bertis Inc (KR) | 2024-09-04 | — | — | EP | disclosed |
| CN-118496232-A | Compound targeting tyrosine protein kinase BTK and application thereof | 北京康特莱斯医药科技有限公司 | 2024-08-16 | — | — | CN | disclosed |
| WO-1999065866-A1 | ANTHRACENE DERIVATIVES AS ANTI-CANCER AGENTS | BTG INTERNATIONAL LIMITED (GB) | 1999-12-23 | — | — | WO | disclosed |
| US-5496805-A | DIURETIC, HYPOTENSIVE | E. R. SQUIBB & SONS, INC. (US) | 1996-03-05 | — | — | US | disclosed |
| US-5220029-A | N-acyl derivatives of thiazolinone hydazones | VITEK SYSTEMS, INC. (US) | 1993-06-15 | — | — | US | disclosed |
| US-RE34284-E | Contacting sample with enzyme reactive acyl thiazolinone hydrazone compound, adding oxidative coupling agents and oxidizing agents, monitoring increase in absorbance | BIOMERIEUX VITEK, INC. (US) | 1993-06-15 | — | — | US | disclosed |
| US-4950593-A | USING THIAZOLINONE HYDRAZONE | VITEK SYSTEMS, INC. (US) | 1990-08-21 | — | — | US | disclosed |
| US-4847286-A | ANTIALLERGENS | KYOTO PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 1989-07-11 | — | — | US | disclosed |
| EP-0233946-A1 | CHROMOGLYCIC ACID DERIVATIVES, PROCESS FOR THEIR PREPARATION, AND MEDICINAL COMPOSITION | Kyoto Pharmaceutical Industries, Ltd. (JP) | 1987-09-02 | — | — | EP | disclosed |
| US-4525576-A | HIGH MOLECULAR WEIGHT, FROM DIPEPTIDE ACTIVE ESTER ACID SALT IN APROTIC SOLVENT WITH TERIARY AMINE ND PHOSPHORUS PENTOXIDE | NITTO BOSEKI CO. LTD. (JP) | 1985-06-25 | — | — | US | disclosed |
| US-4515920-A | Synthesis of peptides and proteins | THE ROCKEFELLER UNIVERSITY (US) | 1985-05-07 | — | — | US | disclosed |
| EP-0138605-A2 | Process for producing sequential polyamino acid resin | NITTO BOSEKI CO., LTD. (JP) | 1985-04-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260091024-A1 | PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE | IL6ST, GFRA3, GFRA1 | CTSS 1265/4885CTSK 1499/4885CTSL 145/4885 |
| US-20260041673-A1 | PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE | GFRA3, IL6ST, GFRA1 | CTSS 1454/4885CTSK 1659/4885CTSL 164/4885 |
| US-12472165-B2 | Riluzole prodrugs and their use | APEH, ALDH1A2, UGT1A9 | CTSS 653/4885CTSK 586/4885CTSL 12/4885 |
| US-12295942-B2 | Riluzole prodrugs and their use | APEH, ALDH1A2, UGT1A9 | CTSS 653/4885CTSK 586/4885CTSL 12/4885 |
| US-20250332148-A1 | RILUZOLE PRODRUGS AND THEIR USE | APEH, ALDH1A2, UGT1A9 | CTSS 653/4885CTSK 586/4885CTSL 12/4885 |
| US-12213965-B2 | Riluzole prodrugs and their use | APEH, ALDH1A2, UGT1A9 | CTSS 653/4885CTSK 586/4885CTSL 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.